

26th October 2017

## **EXTENSION OF DATE FOR ANNUAL GENERAL MEETING**

Respiri Limited (ASX: RSH) (Company) advises that it has sought and gained approval from ASIC to extend the time within which Respiri must hold its Annual General Meeting for 2017.

The Company was due to hold its AGM by 30 November 2017. Following ASIC's approval for an extension, the Company must now hold its AGM by 14 December 2017.

The extension was sought to provide the Company with sufficient time to consider whether the Notice of Intention received by the Company and announced by the Company on 17 October 2017 complied with the Corporations Act 2001 (Cth).

The Notice of Meeting for the AGM is expected to be mailed to shareholders in the coming weeks.

**Leon L'Huillier**  
Chairman

Ph: 1800 476 632

## About Respi

Respiri Limited (ASX:RSH) is a health technology company leading the way in the development of innovative devices and mobile health apps to improve the management of chronic and costly respiratory disorders such as asthma and COPD. Building on decades of experience in the research and development of cutting-edge clinical products for hospitals, the company has first-mover advantage in providing broad access to its proprietary acoustic based clinical solutions for remote monitoring with the development of a suite of over-the-counter connected devices.

Health authorities universally agree that mHealth solutions can transform asthma care and health conscious consumers are rapidly embracing patient self-management with the aid of smartphones, the growth engine for Respi's flagship product, AirSonea®. With the addition of new products, including a connected device for nocturnal monitoring in development, Respi has a captive market, globally, of parents and carers of young children who cannot perform lung function tests. Respi products have been cleared for use by the US Food and Drug Administration, the European Union CE, the Australian TGA and the commencement of an approval process for Asian markets has begun.

Respiri is especially proud of its recent de-risking of milestones. The substantial achievements over the past 18 months place Respi in a lower risk position and on the cusp of commercialisation compared to the vast majority of medical device and biotech companies.